JAK1 and keloid: Consistent with these reports, the accelerated wound closure in the keloid cell line was blocked by the JAK1/2 inhibitor ruxolitinib (Fig 1D) while also inhibiting closure time in the HV fibroblast line in a dose-dependent manner (Fig 1E and 1F).